Policy | March 19, 2025
Anupriya Patel inaugurates India Innovation Summit – Pioneering Solutions to End TB
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
WuXi XDC's fully integrated ADC discovery service platform will significantly boost the speed and efficiency of LigaChem's ADC development programs
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Subscribe To Our Newsletter & Stay Updated
